Search

Copyright of Packaging & Food Machinery is the property of Packaging & Food Machinery Magazine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the therapeutic efficacy and safety of the combination of monosialotetrahexosylganglioside ( GM1) injection and Batroxobin in treating sudden deafness. Methods The clinical data of 162 patients with sudden deafness in Affiliated Hospital of Tangshan Vocational and Technical College between January 2018 and December 2022 were selected for retrospective analysis and grouped according to the treatment protocol，81 cases in the control group were treated with batroxobin and 81 cases in the observation group were treated with GM1 injection combined with batroxobin. The efficacy and symptom recovery time of the 2 groups were compared，as well as the levels of pure tone hearing threshold，inflammatory indexes [interleukin-10 (IL-10), high sensitive C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) ] before and after treatment，and safety. Results The total effective rate of the observation group was 92.59%，which was higher than that of the control group (59.26%) (P < 0.05) ; the observation group had shorter time for dizziness to disappear， hearing to return to normal，and tinnitus to disappear than the control group (P < 0.05) ; pure tone hearing thresholds in the observation group were lower than those in the control group after 7 d and 14 d of treatment (P > 0.05) ; after treatment，the serum IL-10 level in the observation group was higher than that in the control group，while the levels of hs-CRP and TNF-α were lower than those in the control group (P < 0.05) ; the incidence of adverse reactions in the observation group was 11.11%，compared with 9.88% in the control group，the difference was not statistically significant ( P > 0.05) . Conclusion GM1 injection combined with batroxobin can effectively control the inflammatory response in patients with sudden deafness，improve hearing status，accelerate the recovery process， and has a certain degree of safety and efficacy. [ABSTRACT FROM AUTHOR]

随着程序性死亡受体1（PD-1) 、程序性死亡配体1（PD-L1) 以及细胞毒性T淋巴细胞抗原4（CTLA-4) 等免 疫检查点的发现，免疫检查点抑制剂（ICI) 逐渐成为肿瘤治疗领域中最有前景的方法之一，已被证实可以提高晚期 非小细胞肺癌（NSCLC) 患者的生存率。与化疗相比，对于肿瘤细胞表面PD-L1高表达的晚期NSCLC患者，抗PD-1/ PD-L1治疗后生存期显著延长且不良反应较少。抗 CTLA-4药物单药治疗效果有限，通常与 PD-1/PD-L1药物联合 可进一步提高抗肿瘤效果。另外一些新型免疫检查点抑制剂，如依吉利单抗、替拉戈鲁单抗等在临床试验中也表现 出一定的抗肿瘤作用，未来在晚期NSCLC患者的治疗中或许能提供帮助。对ICI在NSCLC治疗中的临床应用进行 总结，同时对未来免疫治疗的发展和预测性生物标志物进行展望，可以为晚期NSCLC患者的治疗提供新的靶点和 思路。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Acta Sedimentologica Sinica is the property of Acta Sedimentologica Sinica Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)